Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021GlobeNewsWire • 02/04/21
Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drugMarket Watch • 01/25/21
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™Business Wire • 01/25/21
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 ResultsGlobeNewsWire • 01/10/21
3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)Zacks Investment Research • 01/07/21
Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 01/06/21
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/06/21
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for ProphylaxisGlobeNewsWire • 12/29/20
Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/05/20
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 10/29/20
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 10/21/20
Emergent Biosolutions (EBS) Gains As Market Dips: What You Should KnowZacks Investment Research • 10/15/20
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020GlobeNewsWire • 10/15/20